Creatine Kinase MM

Added to your cart

Creatine Kinase MM

Cart subtotal: £0.00

View cart (0) Checkout

#SKU P189-9

£113.00

Price excludes shipping costs.
To view our shipping costs click here.

Need to order this product in bulk?

Contact our team of experts to discuss your bulk requirements

Contact our expert team

Product Details

Creatine kinases are found in muscle tissues and are released into the bloodstream following muscle damage. Creatine Kinase consists of 2 subunits; M and B. Combinations of the two subunits results in the isomers CK-MB, CK-MM and CK-BB. Measurement of the CK-MB isoenzyme, found in cardiac muscle, is routinely used as a marker for myocardial infarction (MI).

100 Units
P189-9

More information

Attributes

Description

  • Shipping Information
  • Dry Ice
  • Abbreviations
  • CKMM
  • Specification
  • > 100 U/mg
  • Recommended Use
  • Research and further manufacturing
  • Storage
  • Below -15°C
  • Buffer
  • 40 mM Tris-HCl buffer, pH 7.5, containing 1mM EDTA, 10mM n-Acetyl cysteine
  • Disease Area
  • Cardiac
  • Presentation Matrix
  • lyophilised in 40mM Tris-HCl buffer, pH 7.5, containing 1mM EDTA, 10mM n-Acetyl cysteine
  • Purity/grade
  • >10%
  • Source
  • Cardiac Tissue
  • Applications
  • Biosensors, Clinical Chemistry, Control Manufacture, ELISA, Lateral Flow, Life Science

Technical Documents

Certificates Of Analysis (78.5KB)

Safety Data Sheet (27.94KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox